1. Home
  2. SND vs LYEL Comparison

SND vs LYEL Comparison

Compare SND & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Smart Sand Inc.

SND

Smart Sand Inc.

N/A

Current Price

$3.82

Market Cap

215.0M

Sector

Industrials

ML Signal

N/A

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

N/A

Current Price

$14.77

Market Cap

195.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SND
LYEL
Founded
2011
2018
Country
United States
United States
Employees
318
N/A
Industry
Mining & Quarrying of Nonmetallic Minerals (No Fuels)
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
215.0M
195.8M
IPO Year
2016
2021

Fundamental Metrics

Financial Performance
Metric
SND
LYEL
Price
$3.82
$14.77
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
★ $37.88
AVG Volume (30 Days)
★ 199.0K
193.2K
Earning Date
11-20-2026
11-04-2026
Dividend Yield
★ 6.39%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 0.15
N/A
Revenue
★ $330,153,000.00
$36,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$29.13
★ N/A
Revenue Growth
★ 6.03
N/A
52 Week Low
$2.09
$7.20
52 Week High
$5.92
$45.00

Technical Indicators

Market Signals
Indicator
SND
LYEL
Relative Strength Index (RSI) 21.77 75.02
Support Level $3.64 $11.87
Resistance Level $5.39 $14.97
Average True Range (ATR) 0.24 1.22
MACD -0.12 0.73
Stochastic Oscillator 3.62 77.65

Price Performance

Historical Comparison
SND
LYEL

About SND Smart Sand Inc.

Smart Sand Inc. is a fully integrated frac sand company providing mine-to-well site proppant supply and logistics. It produces Northern White frac sand for enhanced hydrocarbon recovery in oil and gas wells. The company offers products like Smart System, SmartBelt, SmartDepot Silo, and SmartPath Loader. It is expanding into industrial markets, including glass, ceramics, and renewable energy, while its main revenue comes from sand sales and logistics. The company has two reportable segments, Sand and SmartSystems. It derives maximum revenue from Sand segment, which includes both frac sand sales and IPS sales. Geographically, the company derives maximum revenue from United States, followed by Canada.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: